Acologix, Toray Industries to Collaborate in Development of Drug Candidate for Renal Disease.Tokyo, Japan, June 22, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Toray Industries recently announced that it has concluded a licensing agreement with Acologix, a California biopharmaceutical company specializing in the field of osteo-renal diseases, for AC-200 (phosphatonin), a drug candidate being developed by Acologix. AC-200 is a recombinant protein recombinant protein Molecular biology A protein encoded by recombinant DNA or generated from a recombinant gene. See Recombinant pharmacology. intended for the treatment of hyperphosphatemia. Hyperphosphatemia, which is a common symptom of patients in the terminal or advanced stages of chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be , induces severe conditions like cardiovascular episodes and bone disease. Under the agreement, Toray will have an exclusive license to AC-200 in Japan. Going forward, Acologix will proceed with the development of AC-200, in which Toray may participate to a certain extent. Details of the agreement are yet to be announced To be announced (TBA) A contract for the purchase or sale of an MBS to be delivered at an agreed-upon future date but does not include a specified pool number and number of pools or precise amount to be delivered. . Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion